Newron Pharmaceuticals S.p.A. (NWRN) FDA U.S. Hold on ENIGMA-TRS 2 Enrollment Remains

Newron said the FDA will keep the U.S. enrollment hold for Phase 3 ENIGMA-TRS 2 after an external sudden death report; enrollment continues ex-U.S. with site expansion. Topline ENIGMA-TRS 1 12-week data are expected in Q1 2027.Material DetailsContext by AI AnalystThis update extends a known U.S. re…